De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?
The synergistic blockade of the key platelet signaling pathways of cyclooxygenase-1 blockade and P2Y12 signaling by combining aspirin plus a potent P2Y12 inhibitor (prasugrel or ticagrelor), the so called dual antiplatelet treatment (DAPT), has represented the antithrombotic regimen of choice in pat...
Main Authors: | Mattia Galli, Dominick J. Angiolillo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.975969/full |
Similar Items
-
De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
by: Chen Guo, et al.
Published: (2020-01-01) -
Efficacy and safety of different dual antiplatelet strategies in patients undergoing percutaneous coronary intervention: A systematic review and network meta‐analysis
by: Yuttana Wongsalap, et al.
Published: (2023-12-01) -
The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01) -
Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
by: Jialun Han, et al.
Published: (2023-03-01) -
Antiplatelet Therapy in Acute Coronary Syndrome
by: I. M. Kuzmina, et al.
Published: (2022-01-01)